(-) Development pipeline (AstraZeneca) - Feb 2, 2012 - Discontinued in asthma for safety / efficacy
Discontinued • Immunology
|
|
enokizumab (MEDI-528)
Development Pipeline - Discontinued Projects between 27 January 2011 and 31 December 2011
Reason for Discontinuation: Safety/Efficacy
Area Under Investigation: asthma
|